Ray Monika, Fenton Joshua J, Romano Patrick S
Department of Internal Medicine, School of Medicine, University of California Davis, Davis, California, United States of America.
Center for Healthcare Policy and Research, University of California Davis, Davis, California, United States of America.
PLOS Digit Health. 2025 Apr 7;4(4):e0000785. doi: 10.1371/journal.pdig.0000785. eCollection 2025 Apr.
Chronic pain is commonly treated with long-term opioid therapy, but rapid opioid dose tapering has been associated with increased adverse events. Little is known about heterogeneity in the population of patients on high dose opioids and their response to different treatments. Our aim was to examine opioid dose management and other patient characteristics in a longitudinal, clinically diverse, national population of opioid dependent patients. We used spectral clustering, an unsupervised artificial intelligence (AI) approach, to identify patients in a national claims data warehouse who were on an opioid dose tapering regimen from 2008-2018. Due to the size and heterogeneity of our cohort, we did not impose any restrictions on the kind or number of clusters to be identified in the data. Of 113,618 patients with 12 consecutive months at a stable mean opioid dose of ≥ 50 morphine milligram equivalents, 30,932 had one tapering period that began at the first 60-day period with ≥ 15% reduction in average daily dose across overlapping 60-day windows through 7 months of follow-up. We identified 10 clusters that were similar in baseline characteristics but differed markedly in the magnitude, velocity, duration, and endpoint of tapering. A cluster comprising 42% of the sample, characterised by moderately rapid, steady tapering, often (73%) to a final dose of zero, had excess drug-related events, mental health events, and deaths, compared with a cluster comprising 55% of the sample, characterised by slow, steady tapering. Four clusters demonstrated tapers of various velocities followed by complete or nearly complete reversal, with combined drug-related event rates close to that of the slowest tapering cluster. Unsupervised AI methods, such as spectral clustering, are powerful to identify clinically meaningful patterns in opioid prescribing data and to highlight salient subpopulation characteristics for designing safe tapering protocols. They are especially useful for identifying rare events in large data. Our findings highlight the importance of considering tapering velocity along with duration and final dose and should stimulate research to understand the causes and consequences of taper reversals in the context of patient-centered care.
慢性疼痛通常采用长期阿片类药物治疗,但快速减少阿片类药物剂量与不良事件增加有关。对于高剂量阿片类药物患者群体的异质性及其对不同治疗的反应,我们知之甚少。我们的目的是在一个纵向的、临床情况多样的全国阿片类药物依赖患者群体中,研究阿片类药物剂量管理及其他患者特征。我们使用谱聚类这一无监督人工智能方法,在一个全国性理赔数据仓库中识别出2008年至2018年期间处于阿片类药物剂量递减方案的患者。由于我们队列的规模和异质性,我们没有对数据中要识别的聚类类型或数量施加任何限制。在113,618名连续12个月平均阿片类药物稳定剂量≥50毫克吗啡当量的患者中,30,932人有一个减量期,该减量期始于第一个60天期间,在7个月的随访中,跨重叠60天窗口的平均每日剂量减少≥15%。我们识别出10个聚类,它们在基线特征上相似,但在减量的幅度、速度、持续时间和终点方面有显著差异。一个占样本42%的聚类,其特征是减量适度快速且稳定,通常(73%)最终剂量减至零,与一个占样本55%、特征为减量缓慢且稳定的聚类相比,有更多与药物相关的事件、心理健康事件和死亡。四个聚类表现出不同速度的减量,随后完全或几乎完全逆转,与药物相关的事件综合发生率接近减量最慢的聚类。无监督人工智能方法,如谱聚类,对于在阿片类药物处方数据中识别具有临床意义的模式以及突出显著的亚群体特征以设计安全的减量方案很强大。它们对于在大数据中识别罕见事件特别有用。我们的研究结果强调了在考虑减量持续时间和最终剂量的同时也要考虑减量速度的重要性,并应激发研究以了解在以患者为中心的护理背景下减量逆转的原因和后果。